These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 11413323)

  • 1. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.
    Scharf O; Golding H; King LR; Eller N; Frazier D; Golding B; Scott DE
    J Virol; 2001 Jul; 75(14):6558-65. PubMed ID: 11413323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization.
    Cavacini LA; Emes CL; Power J; Duval M; Posner MR
    J Immunol; 1994 Mar; 152(5):2538-45. PubMed ID: 7510748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses.
    Goncalvez AP; Men R; Wernly C; Purcell RH; Lai CJ
    J Virol; 2004 Dec; 78(23):12910-8. PubMed ID: 15542643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals.
    Cavacini LA; Kuhrt D; Duval M; Mayer K; Posner MR
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):785-92. PubMed ID: 14585209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities.
    Gupta CK; Leszczynski J; Gupta RK; Siber GR
    Biologicals; 1996 Jun; 24(2):117-24. PubMed ID: 8889058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding characteristics of dimeric IgG subclass complexes to human neutrophils.
    Huizinga TW; Kerst M; Nuyens JH; Vlug A; von dem Borne AE; Roos D; Tetteroo PA
    J Immunol; 1989 Apr; 142(7):2359-64. PubMed ID: 2784461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.
    Cavacini LA; Emes CL; Power J; Desharnais FD; Duval M; Montefiori D; Posner MR
    J Immunol; 1995 Oct; 155(7):3638-44. PubMed ID: 7561063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two different preparations of HIV immune globulin for efficiency of neutralization of HIV type 1 primary isolates.
    Nichols CN; Bernal I; Prince AM; Andrus L
    AIDS Res Hum Retroviruses; 2002 Jan; 18(1):49-56. PubMed ID: 11804556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes.
    Falkenburg WJ; van Schaardenburg D; Ooijevaar-de Heer P; Tsang-A-Sjoe MW; Bultink IE; Voskuyl AE; Bentlage AE; Vidarsson G; Wolbink G; Rispens T
    J Immunol; 2017 Jan; 198(1):82-93. PubMed ID: 27864476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
    Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
    Front Immunol; 2021; 12():733958. PubMed ID: 34566999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of IgG subclasses to human cytomegalovirus.
    Gilljam G; Wahren B
    J Virol Methods; 1989 Aug; 25(2):139-51. PubMed ID: 2550502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus.
    Men R; Yamashiro T; Goncalvez AP; Wernly C; Schofield DJ; Emerson SU; Purcell RH; Lai CJ
    J Virol; 2004 May; 78(9):4665-74. PubMed ID: 15078949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects.
    Raux M; Finkielsztejn L; Salmon-Céron D; Bouchez H; Excler JL; Dulioust E; Grouin JM; Sicard D; Blondeau C
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):583-94. PubMed ID: 10777149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding site and subclass specificity of the herpes simplex virus type 1-induced Fc receptor.
    Wiger D; Michaelsen TE
    Immunology; 1985 Mar; 54(3):565-72. PubMed ID: 2982735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization capacity and antibody dependent cell-mediated cytotoxicity of separated IgG subclasses 1, 3 and 4 against herpes simplex virus.
    Mathiesen T; Persson MA; Sundqvist VA; Wahren B
    Clin Exp Immunol; 1988 May; 72(2):211-5. PubMed ID: 2842096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flexibility of human IgG subclasses.
    Roux KH; Strelets L; Michaelsen TE
    J Immunol; 1997 Oct; 159(7):3372-82. PubMed ID: 9317136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event.
    McInerney TL; McLain L; Armstrong SJ; Dimmock NJ
    Virology; 1997 Jul; 233(2):313-26. PubMed ID: 9217055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.
    Zhu Z; Dimitrov AS; Bossart KN; Crameri G; Bishop KA; Choudhry V; Mungall BA; Feng YR; Choudhary A; Zhang MY; Feng Y; Wang LF; Xiao X; Eaton BT; Broder CC; Dimitrov DS
    J Virol; 2006 Jan; 80(2):891-9. PubMed ID: 16378991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis.
    Persselin JE; Stevens RH
    J Clin Invest; 1985 Aug; 76(2):723-30. PubMed ID: 3928684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.